financetom
Business
financetom
/
Business
/
Otter Tail's Q1 Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Otter Tail's Q1 Earnings, Revenue Rise
May 7, 2024 2:07 AM

04:55 AM EDT, 05/07/2024 (MT Newswires) -- Otter Tail (OTTR) reported Q1 earnings late Monday of $1.77 per diluted share, up from $1.49 a year earlier.

Three analysts polled by Capital IQ expected $1.45.

Revenue for the quarter ended March 31 was $347.1 million, compared with $339.1 million a year earlier.

Three analysts surveyed by Capital IQ expected $353.7 million.

The company increased its full-year 2024 earnings guidance to $6.23 to $6.53 per diluted share from $5.13 to $5.43 previously. Three analysts polled by Capital IQ expect $5.30.

Price: 95.49, Change: +4.83, Percent Change: +5.33

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Turtle Beach's PDP Acquisition Seen Driving Over $400 Million in Revenue in 2025, Wedbush Says
Turtle Beach's PDP Acquisition Seen Driving Over $400 Million in Revenue in 2025, Wedbush Says
Mar 14, 2025
08:33 AM EDT, 03/14/2025 (MT Newswires) -- Turtle Beach's ( TBCH ) takeover of Performance Designed Products, or PDP, is going very well and it is expected to generate more than $400 million in total revenue in 2025, Wedbush said in a Friday note. There should be meaningful earnings before interest, taxes, depreciation, and amortization over the next several quarters...
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation
Mar 14, 2025
08:38 AM EDT, 03/14/2025 (MT Newswires) -- Korro Bio ( KRRO ) said Friday that the US Food and Drug Administration has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of alpha-1 antitrypsin deficiency, or AATD. AATD is a genetic disorder that can cause pulmonary emphysema and/or hepatic cirrhosis, Korro Bio ( KRRO ) said. Korro...
China's CATL sees slowest profit growth in six years
China's CATL sees slowest profit growth in six years
Mar 14, 2025
BEIJING (Reuters) - CATL reported 15% growth in 2024 net profit, the slowest pace in six years, as a prolonged price war in China's electric vehicle market put pressure on the Chinese EV battery giant. Net profit was up 15% last year to 50.7 billion yuan ($7.01 billion), versus its forecast of 11.1-20.1%, according to a stock filing on Friday....
Bristol-Myers Squibb Says EU Approves Breyanzi for Relapsed, Refractory Follicular Lymphoma
Bristol-Myers Squibb Says EU Approves Breyanzi for Relapsed, Refractory Follicular Lymphoma
Mar 14, 2025
08:44 AM EDT, 03/14/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that Breyanzi has received approval from the European Commission for the treatment of adult patients with relapsed or refractory follicular lymphoma. The additional approval is based on results of a phase 2 study, where Breyanzi showed a high overall response rate of 97.1% and complete response...
Copyright 2023-2026 - www.financetom.com All Rights Reserved